Elevated PAI-1 Levels May Predict Type 2 Diabetes Before Blood Sugar Rises: Study Suggests

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-03-01 03:15 GMT   |   Update On 2025-03-01 03:15 GMT

Sweden: New research suggests that elevated levels of plasminogen activator inhibitor-1 (PAI-1) in individuals without diabetes may serve as an early warning sign for the future development of type 2 diabetes mellitus (T2DM). The study found that higher levels of PAI-1 in non-diabetic individuals were associated with an increased risk of developing diabetes.

"After accounting for multiple factors, those with elevated baseline PAI-1 had a 1.87 times higher risk. The association was even stronger in individuals with normal glucose levels (OR: 2.68), highlighting the potential of PAI-1 as an early biomarker for assessing diabetes risk," the researchers reported in Diabetology & Metabolic Syndrome.

Plasminogen activator inhibitor-1 (PAI-1), a key regulator of the fibrinolytic system primarily secreted by adipose tissue, plays a crucial role in blood clot regulation. While it is well known for its association with cardiovascular disease, recent research has highlighted its potential involvement in metabolic disorders, including type 2 diabetes. Emerging evidence suggests that elevated PAI-1 levels may serve as an early risk marker for diabetes.

Lars Johansson, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, and colleagues present findings from a large prospective analysis investigating the link between PAI-1 levels and the development of type 2 diabetes mellitus.

For this purpose, the researchers conducted a prospective case-referent study within the Västerbotten Intervention Programme (VIP). Between 1990 and 2005, data on cardiovascular risk factors, fasting plasma glucose (FPG), and 2-hour plasma glucose (2-hPG) were collected during baseline health examinations. Blood samples were stored for future analysis, and participants followed over time.

During the study period, 484 individuals developed type 2 diabetes. An equal number of referents without diabetes were matched based on sex, age, and year of participation. Baseline plasma samples were analyzed for PAI-1 levels, with a subgroup analysis conducted on 201 cases and 201 matched referents with normal baseline glucose levels (FPG <6.1 and 2-hPG <8.9 mmol/L).

The following were the key findings of the study:

  • Higher baseline PAI-1 levels were linked to an increased risk of developing type 2 diabetes, even after adjusting for BMI, family history of diabetes, smoking status, hypertension, FPG, and 2-hPG (OR = 1.87).
  • In a subgroup analysis of 201 participants with normal glucose levels at the time of the health examination, elevated PAI-1 levels were associated with an even higher risk of diabetes (OR = 2.68).

"The findings showed that elevated PAI-1 levels in individuals without diabetes may serve as an early indicator of type 2 diabetes, appearing before any detectable rise in fasting plasma glucose or 2-hour plasma glucose," the researchers concluded.

Reference:

Hernestål-Boman, J., Öhman, T., Jansson, JH. et al. Elevated levels of PAI-1 precede the occurrence of type 2 diabetes mellitus. Diabetol Metab Syndr 17, 61 (2025). https://doi.org/10.1186/s13098-025-01629-4


Tags:    
Article Source : Diabetology & Metabolic Syndrome

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News